A-TAP - Arthritis Therapy Acceleration Programme
The Arthritis Therapy Acceleration Programme (A-TAP) is an exciting new £7M concept funded by the Kennedy Trust for Rheumatology Research. It brings together the Universities of Birmingham and Oxford and seven NHS partners and is supported by our access to over 7million patients. The initiative is aiming to support and develop novel treatments for arthritis based on the underlying causes of inflammatory disease.
This ambition is facilitated by our innovative new approach to translational inflammation research through our application of unique rigorous signal seeking experimental medicine studies leading to rapid adoption into clinical trials underpinned by novel trial design. The results will help us treat the cause of disease not just their symptoms and help develop a new taxonomy of disease that moves away from a traditional “organ-based, speciality-focussed” approach to a process-driven, pathway-focussed classification for inflammatory diseases.
Latest news from the Kennedy Institute
20 January 2020
A new study published in Nature Communications identifies a key driver of joint and intestinal inflammation that could lead to future treatment of the chronic inflammatory disease.
15 January 2020
Researchers have uncovered how tumors exploit tenascin-C to deflect the body’s natural defence against them.
6 December 2019
A new study published in the Journal of Experimental Medicine reveals how IL-10 and PGE2 work together to prevent inflammatory tissue damage and maintain a healthy gut balance
12 November 2019
Jagdeep Nanchahal, Professor of Hand, Plastic and Reconstructive Surgery at the Kennedy Institute, and his team have won the International Dupuytren Award for a trial repurposing anti-TNF in Dupuytren’s disease.